a public good project by the
Synthesis
Company
of California

© 2026

Jean‐Jacques Grob | doi.page

0 works0 citations0 h-index

Jean‐Jacques Grob

Aix-Marseille Université(FR)Institut de Neurosciences de la Timone(FR)Hôpital de la Timone(FR)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Nonmelanoma Skin Cancer Studies

Most-Cited Works

→ Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
→ Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
→ Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
→ Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
→ Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
→ Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial(2012)2,954 cited

→ Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial(2015)

2,648 cited

→ Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited

→ Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial(2015)1,372 cited

→ Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma(2019)1,338 cited